Severity
Moderate
FDA Drug recall · Reported November 23, 2022
CGMP Deviations: Potential for cross contamination due to product carry over.
Nephron Sterile Compounding Center LLC recalled PF-Labetalol HCl Injection, USP 20 mg/4 mL (5 mg/mL) vial, Rx Only, Nephron 503B Outsourc… - a moderate-severity action.
PF-Labetalol HCl Injection, USP 20 mg/4 mL (5 mg/mL) vial, Rx Only, Nephron 503B Outsourc… was recalled by Nephron Sterile Compounding Center LLC in November 23, 2022. Reason: CGMP Deviations: Potential for cross contamination due to product carry over.. Check the official notice for the remedy. Verify recall #D-0064-2023 with the FDA Drug before acting.
The recall
Nephron Sterile Compounding Center LLC issued this moderate-severity FDA Drug recall-CGMP Deviations: Potential for cross contamination due to product carry over..
Sourced from official FDA Drug enforcement records. Verify recall #D-0064-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0064-2023) was formally reported on November 23, 2022, with the manufacturer initiating the action on November 10, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Nephron Sterile Compounding Center LLC is listed as the recalling firm, operating out of West Columbia, SC. Federal records list the affected scope as 34,020 vials.
The documented reason for this recall is: CGMP Deviations: Potential for cross contamination due to product carry over. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
34,020 vials
Related Recalls
6
5 from same agency
PF-Labetalol HCl Injection, USP 20 mg/4 mL (5 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-946-34, UPC 3 69374 94634 6.
CGMP Deviations: Potential for cross contamination due to product carry over.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0064-2023 |
| Date reported | November 23, 2022 |
| Date initiated | November 10, 2022 |
| Recalling firm | Nephron Sterile Compounding Center LLC |
| Firm location | West Columbia, SC |
| Affected scope | 34,020 vials |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 23, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.